

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claim 1 (canceled)

Claim 2 (canceled)

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (currently amended): A compound of formula I,



wherein

W is O or S;

X is NR₈;

Y is CR₉R₁₀-(CH₂)_n wherein

R₉ and R₁₀ are independently of each other hydrogen or lower alkyl, and

n is an integer of from and including 0 to and including 3; or

Y is SO₂;

R₁ is aryl;

R₂ is a ~~mono- or bicyclic~~ heteroaryl group comprising ~~one two~~ or more ring nitrogen atoms ~~with the exception that R₂ cannot represent 2-phthalimidyl, and in case of Y = SO₂ cannot represent 2,1,3-benzothiadiazol-4-yl;~~

any of R₃, R₄, R₅ and R₆, independently of the other, is H or a substituent other than hydrogen; and

R₇ and R₈, independently of each other, are H or lower alkyl;

~~with the exception of the compound of formula I wherein W is O, X is NR₈, Y is CH₂, R₁ is 4-chlorophenyl, R₂ is 2-pyridyl, R₃, R₄, R₅, R₇ and R₈ are each H and R₆ is chloro;~~
or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 6 (currently amended): A compound of formula I according to claim 5,

wherein

W is O or S;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein

R₉ is hydrogen or lower alkyl, and

n is an integer of from and including 0 to and including 3; or

Y is SO₂;

R₁ is aryl;

R₂ is a ~~mono- or bicyclic~~ heteroaryl group comprising ~~one two~~ or more ring nitrogen atoms ~~with the exception that R₂ cannot represent 2-phthalimidyl, and in case of Y = SO₂ cannot represent 2,1,3-benzothiadiazol-4-yl;~~

any of R₃, R₄, R₅ and R₆, independently of the other, is H or a substituent other than hydrogen; and

R₇ and R₈, independently of each other, are H or lower alkyl;

~~with the exception of the compound of formula I wherein W is O, X is NR₈, Y is CH₂, R₁ is 4-chlorophenyl, R₂ is 2-pyridyl, R₃, R₄, R₅, R₇ and R₈ are each H and R₆ is chloro;~~
or a salt thereof.

Claim 7 (currently amended): A compound of formula I according to claim 5,

wherein

W is O or S;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein

R₉ is H or lower alkyl, and


n is 0 to 3; or

Y is SO₂;


R₁ is phenyl that is unsubstituted or substituted by up to three substituents selected from amino, mono- or disubstituted amino wherein the substituents are selected independently from lower alkyl, hydroxy-lower alkyl, phenyl-lower alkyl, lower alkanoyl, benzoyl and substituted benzoyl wherein the phenyl

radical is substituted by one or two substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower-alkoxycarbonyl, lower alkanoyl and carbamoyl, and phenyl-lower alkoxycarbonyl wherein the phenyl radical is substituted by one or two substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower-alkoxycarbonyl, lower alkanoyl and carbamoyl; lower alkyl; substituted lower alkyl where up to three substituents are present independently selected from the group containing halogen, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoyl-amino, hydroxy, cyano, carboxy, lower alkoxycarbonyl and phenyl-lower alkoxycarbonyl; hydroxy, lower alkoxy; phenyl-lower alkoxy; phenyloxy; halogen-lower alkoxy, lower alkanoyloxy; benzoyloxy; lower alkoxycarbonyloxy; phenyl-lower alkoxycarbonyloxy; nitro; cyano; carboxy; lower alkoxycarbonyl; phenyl-lower alkoxycarbonyl; phenyloxycarbonyl; lower alkylcarbonyl; carbamoyl; N-mono- or N,N-disubstituted carbamoyl that is substituted by one or two substituents independently selected from lower alkyl, phenyl-lower alkyl and hydroxy-lower alkyl, at the terminal nitrogen atom; amidino; guanidino; mercapto; sulfo; lower alkylthio; phenylthio; phenyl-lower alkylthio; lower alkyl-phenylthio; lower alkylsulfinyl; phenylsulfinyl; phenyl-lower alkylsulfinyl; lower alkylphenylsulfinyl; lower alkanesulfonyl; phenylsulfonyl; phenyl-lower alkylsulfonyl; lower alkylphenylsulfonyl; lower alkenyl; lower alkanoyl; halogen-lower alkylmercapto; halogen-lower alkylsulfonyl; dihydroxybora (-B(OH)₂); and lower alkylene dioxy bound at adjacent C-atoms of the ring;

R₂ is imidazolyl, ~~quinolyl, naphthyridinyl,~~ or a moiety of the formula Ib or Ic



(Ib)



(Ic)

wherein

r is 0 to 2;

A, B, D, and E are, independently of one another, N or CH, with the stipulation that not more than 2 of these radicals are N; ~~preferably~~; and

Q is lower alkyl, hydroxy, lower alkoxy, lower thioalkyl or halogen;

any of R₃, R₄, R₅ and R₆, independently of the other, is H, fluorine or lower alkyl; and

R₇ and R₈, independently of each other, are H or lower alkyl;

or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 8 (currently amended): A compound of formula I according to claim 5, wherein W is O;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein

R₉ is H or methyl, and

n is 0;

or Y is SO₂;

R₁ is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl which is in each case either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; lower alkoxy; hydroxy; phenyl; phenoxy; halogen-lower alkoxy; halogen-lower alkyl; lower alkoxy-carbonyl; N-lower alkyl carbamoyl; lower alkylsulfinyl; lower alkanesulfonyl; and lower alkoxy-carbonyl lower alkyl;

R₂ is imidazolyl, ~~quinolyl, naphthyridinyl, 2-methyl-pyridin-4-yl, 3-pyridyl or 4-pyridyl~~;

any of R₃, R₄, R₅ and R₆, independently of the other, are H, methyl or chloro; or

R₃ and R₄ together represent methylene dioxy and R₅ and R₆, independently of the other, are H, methyl or chloro; and

R₇ and R₈, independently of each other, are H, fluorine or methyl;

or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 9 (currently amended): A compound of formula I according to claim 5, wherein

W is O;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein

R₉ is H or methyl, and

n is 0;

or Y is SO₂;

R₁ is phenyl which is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; halogen-lower alkyl; lower alkylsulfinyl; and lower alkanesulfonyl;

R₂ is imidazolyl, ~~quinolyl, naphthyridinyl, 2-methyl-pyridin-4-yl, 3-pyridyl or 4-pyridyl~~;

any of R₃, R₄, R₅ and R₆, independently of the other, is H or methyl; and

R₇ and R₈, independently of each other, are H or methyl;

or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 10 (currently amended): A compound of formula I according to claim 5, wherein

W is O;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein

R₉ is H or methyl, and

n is 0;

or Y is SO₂;

R₁ is phenyl which is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; halogen-lower alkyl; lower alkylsulfinyl; and lower alkanesulfonyl;

R₂ is imidazolyl, ~~quinolyl, 2-methyl-pyridin-4-yl or 4-pyridyl;~~

any of R₃, R₄, R₅ and R₆, independently of the other, is H or methyl; and

R₇ and R₈, independently of each other, are H or methyl;

or a salt thereof.

Claim 11 (canceled)

Claim 12 (canceled)

Claim 13 (currently amended): A compound of formula I according to claim 5 selected from

~~2-[(4-pyridyl)methyl]amino-N-[3-fluoro-(4-trifluoromethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-phenylbenzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[4-fluoro-3-(trifluoromethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3-fluoro-5-(trifluoromethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3,5-bis(trifluoromethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3,4-bis(trifluoromethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3-methoxy-5-(trifluoromethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3-(1,1-dimethylethyl)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-(3-cyanophenyl)benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[(3-methylthio)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-(3-acetylamino)phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3-[(aminocarbonyl)amino]phenyl]benzamide;~~

~~2-[(4-pyridyl)methyl]amino-N-[3-(dimethylamino)phenyl]benzamide;~~

~~5-methoxy-2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~3-methyl-2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~4,5-difluoro-2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N'-methyl-N'-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-[(3-methylsulphonyl)phenyl]benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-[(3-methylsulphinyl)phenyl]benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-[4-(1,1-dimethylethyl)phenyl]benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-(3-chlorophenyl)benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-(3-bromophenyl)benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-(3-methylphenyl)benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-(3-benzoylphenyl)benzamide;~~
~~2-[(4-pyridyl)methyl]amino-N-[3-(aminocarbonyl)phenyl]benzamide;~~
~~2-[(3-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(4-quinoliny)]methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(5-quinoliny)]methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(4-(2-methyl)pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(4-(1,2-dihydro-2-oxo)pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(4-quinoliny)]methyl]amino-N-(4-chlorophenyl)benzamide;~~
~~2-[(2-imidazolyl)methyl]amino-N-(4-chlorophenyl)benzamide;~~
~~2-[2-(4-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[2-(3-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[1-methyl-2-(3-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
~~2-[(1-oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide; and~~
~~2-[(4-pyridyl)methyl]methylamino-N-[3-(trifluoromethyl)phenyl]benzamide;~~
 or a pharmaceutically acceptable salt thereof.


Claim 14 (canceled)

Claim 15 (canceled)

Claim 16 (currently amended): A pharmaceutical preparation, comprising a compound of formula I according to ~~any one of claims 5 to 14~~claim 5, or a N-oxide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier.

Claim 17 (original): A process for the preparation of a compound of formula I according to claim 5, or a N-oxide or a pharmaceutically acceptable salt thereof, characterized in that

a) for the synthesis of a compound of the formula I wherein X represents NR_8 , where R_8 is hydrogen and Y represents $\text{CHR}_9-(\text{CH}_2)_n$, each as indicated for a compound of formula I, and the remaining symbols W, R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 are as defined for a compound of the formula I, an aniline derivative of the formula II



wherein W, R_1 , R_3 , R_4 , R_5 , R_6 and R_7 are as defined for a compound of the formula I, is reacted with a carbonyl compound of the formula III



wherein n, R_2 and R_9 are as defined for a compound of the formula I in the presence of a reducing agent; or

b) for the synthesis of a compound of the formula I wherein X is SO_2 and the remaining symbols R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , W and X are as defined for a compound of the formula I, an aniline derivative of the formula II as defined under process variante a) is reacted with an acid of the formula IVa




or a reactive derivative thereof; or with a compound of formula IVb,



wherein Hal' is chloro, bromo or iodo; or

c) for the synthesis of compounds of the formula I wherein X represents NR_8 , Y represents $\text{CR}_9\text{R}_{10}-(\text{CH}_2)_n$ and the remaining symbols R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are as defined for a compound of the formula I, a halogen derivative of the formula V



wherein Hal represents iodine, bromine or chlorine and W, R_1 , R_3 , R_4 , R_5 , R_6 and R_7 are as defined for a compound of the formula I, is reacted with an amine of the formula VI



wherein n, R_2 , R_8 , R_9 and R_{10} are as defined for a compound of the formula I in the presence of an appropriate catalyst in an inert solvent in the presence of an aprotic base;

where the starting compounds defined in a), b) or c) may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;

any protecting groups in a protected derivative of a compound of the formula I are removed; and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.